BPC-157
Investigación publicada y base de evidencia
BPC-157 is a synthetic pentadecapeptide derived from a fragment of a protein found in gastric juice. The evidence base is overwhelmingly preclinical: several hundred rodent studies report accelerated healing of tendon, ligament, muscle and gastrointestinal tissue, with mechanisms attributed to angiogenesis, VEGFR2 signalling and nitric oxide system modulation. Peer-reviewed human data are limited to a small number of uncontrolled pilot studies and retrospective case series from a single private clinic, plus one ex vivo study on surgically discarded human arterial tissue; a 2026 preprint, not peer reviewed, describes health records of 1,039 people with documented BPC-157 use. No completed randomised controlled trial and no approved formulation exist, and 2025-2026 systematic reviews in orthopaedic journals explicitly characterise the human evidence as insufficient.
- BPC-157 es un pentadecapéptido sintético derivado de una proteína gástrica.
- Estudios en roedores reportaron cicatrización acelerada vía angiogénesis y VEGFR2.
- Los datos humanos revisados por pares son pilotos no controlados de una clínica; sin ECA.
18 estudios · 10 desde 2023 · más reciente 2026
- Estudios citados
- 18
- Publicados en 2023+
- 10
- Artículo más reciente
- 2026
- Última revisión
- oct 2026
Temas recurrentes en la literatura
- tendon and ligament healing
- muscle transection and myotendinous junction repair
- angiogenesis and VEGFR2 signalling
- nitric oxide system modulation
- gut barrier and cytoprotection
- ischemia-reperfusion injury
- regulatory and anti-doping status
Identificadores del compuesto
- CAS
- 137525-51-0
- PubChem
- 9941957
Recomendado por un comité asesor de la FDA.
El 23–24 July 2026 el Comité Asesor de Formulación Farmacéutica de la FDA consideró BPC-157 para la Lista 503A de Sustancias a Granel y recomendó su inclusión en un voto reportado de 8–6 with one abstention. Heard on the first day of the meeting alongside KPV, TB-500 and MOTS-C, and recommended on a divided vote.
Esto no es una aprobación. El comité asesora; no decide. La recomendación no es vinculante, la FDA no ha completado el proceso de reglamentación que cambiaría formalmente algo, y la inclusión en la Lista 503A de Sustancias a Granel no equivale a la aprobación de un medicamento por la FDA. La lista también rige la formulación farmacéutica para pacientes, que es una actividad separada del suministro para uso exclusivo en investigación.
Lo que realmente hizo el voto asesor de julio de 2026 expone el proceso, los otros compuestos considerados y las cuatro cosas que el voto se reporta erróneamente como significando.
Qué es BPC-157, químicamente.
- Fórmula molecular
- C62H98N16O22
- Peso molecular
- 1419.5 g/mol
- Número CAS
- 137525-51-0
- PubChem CID
- 9941957
Estas cifras provienen del registro PubChem para este compuesto y describen la base libre. El péptido liofilizado normalmente se suministra como sal de acetato o trifluoroacetato y contiene agua residual, por lo que la masa de polvo en un vial no es la misma cantidad que sugeriría el peso molecular anterior. La pureza cromatográfica en un certificado de análisis tampoco resuelve esa diferencia — cómo leer un certificado de análisis explica por qué.
18 estudios publicados.
Ordenados por solidez del diseño del estudio, luego por antigüedad. Cada entrada enlaza a su registro fuente para que el hallazgo pueda verificarse contra el artículo en lugar de tomarse bajo nuestra palabra.
- 01Revisión sistemática2025
Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Vasireddi N, et al. · HSS J · systematic review of the BPC-157 literature from an orthopaedic sports medicine perspective
The authors synthesised preclinical evidence for healing of fractures, tendon ruptures, ligament tears and muscle injuries, and noted that BPC-157 lacks FDA approval and is banned in professional sport despite increasing clinical and athlete use.
- 02Clínico humano2026
Rising Use of Unapproved BPC-157 (“Wolverine Peptide”) and Associated Patient-Reported Outcomes Curated from Clinical Notes
Venkatakrishnan A, et al. · Preprints.org · preprint, not peer reviewed; retrospective cohort built from de-identified clinical notes in a U.S. federated health-records network, 1,039 patients with documented BPC-157 use, 2020-2026, curated by a large language model with physician validation
Improvement in pain, wound or tissue healing or function was documented in 79% of 354 users with a recorded response direction and worsening in 5%, with direction unavailable for 685 users. Half of users co-used other agents, including TB-500 (12.9%), and the authors stated the notes cannot establish efficacy or separate BPC-157 effects from co-treatments, placebo effects or reporting bias.
Hallazgo de seguridad reportado. Neuropsychiatric (1.4%), injection-site hypersensitivity (1.4%) and gastrointestinal (1.3%) adverse events were documented during use and were likely under-reported.
- 03Clínico humano2025
Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study
Lee E, et al. · Altern Ther Health Med · uncontrolled open-label pilot; 2 adults, intravenous BPC-157 10 mg on day 1 and 20 mg on day 2 in 250 cc saline over 1 hour
Infusions of up to 20 mg produced no measurable changes in cardiac, liver, kidney, thyroid or blood glucose biomarkers and no reported side effects in the two participants. The authors stated that larger studies are needed to confirm safety.
- 04Clínico humano2024
Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study
Lee E, et al. · Altern Ther Health Med · uncontrolled open-label pilot; 12 women aged 39-76 who had not responded to pentosan polysulfate, single cystoscopic injection of 10 mg BPC-157 around the inflamed bladder area
Ten of twelve patients reported complete resolution of symptoms on the Global Response Assessment questionnaire and the remaining two reported approximately 80 percent improvement, with no reported adverse events. The study had no control group and no blinding.
- 05Clínico humano2021
Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain
Lee E, Padgett B · Altern Ther Health Med · retrospective single-clinic chart review 2019-2020; 17 patients receiving intra-articular BPC 157 alone or combined with thymosin beta-4, 16 reached by telephone follow-up
Patients self-rated pain before injection and the degree and duration of relief afterwards. No validated instruments for function, stiffness, quality of life or activities of daily living were used, and there was no control group.
- 06Animal in vivo2026
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study
Biçer O, et al. · Jt Dis Relat Surg · rat Achilles tendon transection and repair; 32 male Sprague-Dawley rats, 4 groups of 8 (control, BPC-157 10 ug/kg/day, TB-500 60 ug/kg/day, combination), intraperitoneal, 4 weeks
Both peptides were associated with improved histopathological scores and extracellular matrix organisation at four weeks, and the TB-500 group additionally showed a significantly higher maximum load to failure. Combined BPC-157 and TB-500 treatment did not confer additional benefit over either agent alone.
- 07Animal in vivo2026
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury
Yildirim AK, et al. · Sci Rep · rat hind-limb ischemia-reperfusion by abdominal aortic clamping (45 min ischemia, 2 h reperfusion); 24 male Wistar albino rats in 4 groups of 6
BPC 157 administration was associated with reduced markers of oxidative stress, inflammation and apoptosis in the reperfused limb tissue compared with untreated ischemia-reperfusion controls.
- 08Animal in vivo2025
Stable Gastric Pentadecapeptide BPC 157 as Therapy After Surgical Detachment of the Quadriceps Muscle from Its Attachments for Muscle-to-Bone Reattachment in Rats
Matek D, et al. · Pharmaceutics · rat model of complete (rectus) and partial (vastus) quadriceps muscle detachment from bone; per-oral BPC 157 at 10 ug/kg and 10 ng/kg daily, assessed to day 28
Per-oral BPC 157 was reported to produce muscle-to-bone reattachment and restoration of function after both complete and partial quadriceps detachment, compared with non-healing in untreated animals.
- 09Animal in vivo2022
Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs
He L, et al. · Front Pharmacol · rats and dogs; single intravenous dose, single intramuscular doses at three ascending levels, and repeated intramuscular administration
The study characterised elimination half-life, tissue distribution, metabolism and excretion of BPC157 in two species, providing the pharmacokinetic groundwork the compound otherwise lacks.
- 10Animal in vivo2021
Stable Gastric Pentadecapeptide BPC 157 as a Therapy for the Disable Myotendinous Junctions in Rats
Japjec M, et al. · Biomedicines · rat quadriceps tendon dissected from the quadriceps muscle, a myotendinous junction defect that does not heal spontaneously; BPC 157 10 ug/kg and 10 ng/kg intraperitoneally and per-orally
Treated animals showed improved macroscopic, microscopic, biomechanical and functional outcomes at the myotendinous junction, accompanied by changes in eNOS and COX-2 mRNA levels and in oxidative stress and nitric oxide levels.
- 11Animal in vivo2020
Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds.
Xu C, et al. · Regul Toxicol Pharmacol · preclinical toxicology programme: single and repeated dose in mice, rats, rabbits and dogs, plus local tolerance, genotoxicity and embryo-fetal studies
No test-related effects were seen in single-dose studies; repeated dosing was well tolerated in dogs apart from a reversible creatinine decrease at the highest dose; irritation was mild and no genetic or embryo-fetal toxicity was observed.
Hallazgo de seguridad reportado. Repeated dosing in dogs produced a reversible decrease in creatinine at the highest dose; no other toxicity was reported across four species.
- 12Animal in vivo2017
Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation
Hsieh MJ, et al. · J Mol Med (Berl) · chick chorioallantoic membrane assay, endothelial tube formation assay, and rat hind-limb ischemia with laser Doppler flow measurement
BPC 157 increased vessel density in vivo and in vitro and accelerated recovery of blood flow in ischemic rat hind limb. The pro-angiogenic effect was associated with VEGFR2 activation and upregulation.
- 13Animal in vivo2010
Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat
Cerovecki T, et al. · J Orthop Res · rat medial collateral ligament transection followed 90 days, with intraperitoneal, per-oral (drinking water) and topical peptide administration given without a carrier
BPC 157 improved medial collateral ligament healing across all three routes of administration over 90 days after surgical transection.
- 14Animal in vivo2006
Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157
Staresinic M, et al. · J Orthop Res · complete transverse transection of rat quadriceps muscle 1.0 cm proximal to the patella, with systemic BPC 157 given without a carrier
Systemic BPC 157 induced healing of the completely transected quadriceps muscle and maintained that healing with functional restoration, whereas the untreated defect persisted. This is one of the foundational muscle-injury papers.
- 15In vitro2026
Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery
Yildirim AK, et al. · J Clin Med · ex vivo human internal mammary artery rings from elective CABG surgery; n=12 segments, endothelium-intact and denuded, with and without L-NAME
BPC 157 produced a concentration-dependent reduction in phenylephrine-induced contraction, significantly greater in endothelium-intact rings. NOS inhibition with L-NAME attenuated the relaxation and largely abolished the endothelium-dependent advantage.
- 16In vitro2011
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
Chang CH, et al. · J Appl Physiol (1985) · rat tendon explant outgrowth cultures and isolated tendon fibroblasts cultured with or without BPC 157
BPC 157 significantly accelerated the outgrowth of tendon fibroblasts from explants and increased fibroblast survival and migration. This is one of the foundational mechanistic papers for the tendon-healing claim.
- 17Revisión2026
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Mendias CL, et al. · Sports Med · narrative review covering AOD-9604, BPC-157, CJC-1295, FS-344, GHK-Cu, ipamorelin, MOTS-C, sermorelin, SS-31, tesamorelin, Tb4 and TB-500
The review reported that many unapproved peptides show favourable tissue repair and metabolic outcomes in animal models, but that rigorous human safety data are scarce. It also discussed the placebo effect and social media amplification as mediators of perceived peptide efficacy.
- 18Revisión2026
Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs.
Moiz A, et al. · Mo Med · narrative clinical review of unregulated injectable peptides
Classified BPC-157, TB-500 and melanotan-II as unapproved peptides without established human safety profiles and listed risks including contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis and carcinogenesis.
Hallazgo de seguridad reportado. Authors flagged product contamination, impurities and theoretical angiogenesis/carcinogenesis risk for unregulated BPC-157.
Lo que esta evidencia no establece.
There is no completed randomised, placebo-controlled human trial of BPC-157 for any indication, no established human dose, and no long-term human safety data; the only peer-reviewed human reports are two uncontrolled pilot studies and one retrospective chart review, all from the same private clinic, and the one larger observational dataset is a health-records preprint that has not been peer reviewed. Much of the preclinical corpus originates from a small number of closely affiliated research groups, which limits independent replication.
Preguntas comunes sobre la investigación.
- What is BPC-157?
BPC-157 is a synthetic 15-amino-acid peptide fragment derived from a protective protein found in human gastric juice. It is one of the most widely studied compounds in preclinical tissue-repair research.
- How does BPC-157 differ from TB-500?
Both appear in tissue-repair research, but they are unrelated molecules. BPC-157 is a gastric-juice-derived pentadecapeptide studied for tendon, ligament, and gut models; TB-500 is a synthetic fragment of thymosin beta-4 studied for actin regulation and cell migration. The two are frequently co-studied, which is why combined vials exist.
- How long does BPC-157 stay in the body?
The only published pharmacokinetic characterisation of BPC-157 is a 2022 study in rats and dogs, which measured elimination half-life, tissue distribution, metabolism and excretion after a single intravenous dose, single intramuscular doses at three ascending levels, and repeated intramuscular administration. No equivalent human pharmacokinetic study has been published. The peer-reviewed human record consists of two uncontrolled pilot studies and one retrospective chart review, none of which characterised the peptide's disposition.
Disponible en nuestro catálogo
Solo para fines de investigación. No apto para consumo humano, diagnóstico, tratamiento o prevención de ninguna condición. Nada en esta página constituye consejo médico, y ningún estudio resumido aquí debe leerse como una recomendación.